April 27, 2025
Source: drugdu
121
On April 24, China Resources Double Crane(600062) announced that its wholly-owned subsidiary Hainan Shuanghe recently obtained the drug registration certificate for tigecycline for injection issued by the State Food and Drug Administration. The drug is registered as a Class 4 chemical drug, with a specification of 50 mg and an approval number of National Medicine Standard H20253927.
Hainan Shuanghe started the research and development of generic drugs for this drug in December 2021, submitted a marketing authorization application to the National Medical Products Administration on September 20, 2023, and was approved for marketing on April 15, 2025. The announcement mentioned that the cumulative investment in the research and development of this drug was 10.27 million yuan (unaudited). According to market data, the global sales of injectable tigecycline in 2023 were US$218 million, and the total sales in the Chinese market were RMB 848 million.
The announcement pointed out that the launch of this drug will enrich the company's product line, enhance its market competitiveness, and also accumulate experience for subsequent product research and development.
In 2024, China Resources Double-Crane achieved revenue of 11.212 billion yuan and net profit attributable to shareholders of the parent company of 1.628 billion yuan.
https://finance.eastmoney.com/a/202504243387302456.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.